167 related articles for article (PubMed ID: 35260073)
1. ROR2 increases the chemoresistance of melanoma by regulating p53 and Bcl2-family proteins via ERK hyperactivation.
Castro MV; Barbero GA; Máscolo P; Ramos R; Quezada MJ; Lopez-Bergami P
Cell Mol Biol Lett; 2022 Mar; 27(1):23. PubMed ID: 35260073
[TBL] [Abstract][Full Text] [Related]
2. ROR2 has a protective role in melanoma by inhibiting Akt activity, cell-cycle progression, and proliferation.
Castro MV; Barbero GA; Villanueva MB; Grumolato L; Nsengimana J; Newton-Bishop J; Illescas E; Quezada MJ; Lopez-Bergami P
J Biomed Sci; 2021 Nov; 28(1):76. PubMed ID: 34774050
[TBL] [Abstract][Full Text] [Related]
3. TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway.
Xing Y; Liu Y; Liu T; Meng Q; Lu H; Liu W; Hu J; Li C; Cao M; Yan S; Huang J; Wang T; Cai L
Cell Commun Signal; 2018 Jul; 16(1):43. PubMed ID: 30064446
[TBL] [Abstract][Full Text] [Related]
4. The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma.
O'Connell MP; Fiori JL; Xu M; Carter AD; Frank BP; Camilli TC; French AD; Dissanayake SK; Indig FE; Bernier M; Taub DD; Hewitt SM; Weeraratna AT
Oncogene; 2010 Jan; 29(1):34-44. PubMed ID: 19802008
[TBL] [Abstract][Full Text] [Related]
5. ROR2 promotes epithelial-mesenchymal transition by hyperactivating ERK in melanoma.
Castro MV; Barbero GA; Máscolo P; Villanueva MB; Nsengimana J; Newton-Bishop J; Illescas E; Quezada MJ; Lopez-Bergami P
J Cell Commun Signal; 2023 Mar; 17(1):75-88. PubMed ID: 35723796
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of ROR2 attenuates LPS-induced A549 cell injury through JNK and ERK signaling pathways.
Wang Z; Yang L
Immun Inflamm Dis; 2023 Apr; 11(4):e803. PubMed ID: 37102658
[TBL] [Abstract][Full Text] [Related]
7. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
Augustine CK; Toshimitsu H; Jung SH; Zipfel PA; Yoo JS; Yoshimoto Y; Selim MA; Burchette J; Beasley GM; McMahon N; Padussis J; Pruitt SK; Ali-Osman F; Tyler DS
Mol Cancer Ther; 2010 Jul; 9(7):2090-101. PubMed ID: 20571072
[TBL] [Abstract][Full Text] [Related]
9. Apigenin induces apoptosis by regulating Akt and MAPK pathways in human melanoma cell A375SM.
Woo JS; Choo GS; Yoo ES; Kim SH; Lee JH; Han SH; Kim HJ; Jung SH; Park YS; Kim BS; Kim SK; Park BK; Cho SD; Nam JS; Choi CS; Che JH; Jung JY
Mol Med Rep; 2020 Dec; 22(6):4877-4889. PubMed ID: 33174048
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis.
Chetoui N; Sylla K; Gagnon-Houde JV; Alcaide-Loridan C; Charron D; Al-Daccak R; Aoudjit F
Mol Cancer Res; 2008 Jan; 6(1):42-52. PubMed ID: 18234961
[TBL] [Abstract][Full Text] [Related]
11. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
[TBL] [Abstract][Full Text] [Related]
12. Ror2-Src signaling in metastasis of mouse melanoma cells is inhibited by NRAGE.
Lai SS; Xue B; Yang Y; Zhao L; Chu CS; Hao JY; Wen CJ
Cancer Genet; 2012 Nov; 205(11):552-62. PubMed ID: 23142633
[TBL] [Abstract][Full Text] [Related]
13. An ERK-dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs.
Sheridan C; Brumatti G; Elgendy M; Brunet M; Martin SJ
Oncogene; 2010 Dec; 29(49):6428-41. PubMed ID: 20802529
[TBL] [Abstract][Full Text] [Related]
14. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
[TBL] [Abstract][Full Text] [Related]
15. The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.
Yuan Z; Cao K; Lin C; Li L; Liu HY; Zhao XY; Liu L; Deng HX; Li J; Nie CL; Wei YQ
Mol Med; 2011; 17(11-12):1262-74. PubMed ID: 21863213
[TBL] [Abstract][Full Text] [Related]
16. Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation.
Wu AY; Gu LY; Cang W; Cheng MX; Wang WJ; Di W; Huang L; Qiu LH
J Exp Clin Cancer Res; 2019 Apr; 38(1):176. PubMed ID: 31023317
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of urokinase-type plasminogen activator receptor induces apoptosis in melanoma cells by activation of p53.
Besch R; Berking C; Kammerbauer C; Degitz K
Cell Death Differ; 2007 Apr; 14(4):818-29. PubMed ID: 17110957
[TBL] [Abstract][Full Text] [Related]
18. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy.
Zhang X; Qi Z; Yin H; Yang G
Theranostics; 2019; 9(4):1096-1114. PubMed ID: 30867818
[TBL] [Abstract][Full Text] [Related]
19. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
Rooswinkel RW; van de Kooij B; Verheij M; Borst J
Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003
[TBL] [Abstract][Full Text] [Related]
20. LINC00657/miR-26a-5p/CKS2 ceRNA network promotes the growth of esophageal cancer cells via the MDM2/p53/Bcl2/Bax pathway.
Zhang XM; Wang J; Liu ZL; Liu H; Cheng YF; Wang T
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32426838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
